Terauchi Y, Yabe D, Kaneto H, Amano A, et al. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Diabetes Obes Metab 2020;22 Suppl 4:35-47.
PMID: 33404200